54185-42-1

Basic information

• Product Name: 2,4,6,8-TETRACHLOROQUINAZOLINE
• Synonyms: 2,4,6,8-TETRACHLOROQUINAZOLINE
• CAS NO: 54185-42-1
• Molecular Formula: C₈H₂Cl₄N₂
• Molecular Weight: 267.93
• Mol File: 54185-42-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 331.6°C at 760 mmHg
• Flash Point: 184.5°C
• Appearance: /Solid
• Density: 1.697g/cm³
• Vapor Pressure: 0.000296mmHg at 25°C
• Refractive Index: 1.683
• CAS DataBase Reference: 2,4,6,8-TETRACHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6,8-TETRACHLOROQUINAZOLINE(54185-42-1)
• EPA Substance Registry System: 2,4,6,8-TETRACHLOROQUINAZOLINE(54185-42-1)

Safety Data

• Hazardous Substances Data: 54185-42-1(Hazardous Substances Data)

Usage

Description

2,4,6,8-Tetrachloroquinazoline is an organic compound with the molecular formula C9H4Cl4N2. It is characterized by its quinazoline ring structure, which is fused with a benzene ring, and has four chlorine atoms attached to it. 2,4,6,8-TETRACHLOROQUINAZOLINE is known for its chemical stability and diverse reactivity, making it a versatile building block in the synthesis of various organic and pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
2,4,6,8-Tetrachloroquinazoline is used as an intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity allow for the development of new drugs with potential applications in treating a wide range of diseases and medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, 2,4,6,8-tetrachloroquinazoline serves as a valuable intermediate for the synthesis of complex organic molecules. Its chlorine atoms can be replaced with other functional groups, enabling the creation of a diverse array of compounds with different properties and applications.
Overall, 2,4,6,8-tetrachloroquinazoline is a versatile compound with significant potential in both the pharmaceutical and organic synthesis industries, contributing to the development of new drugs and organic compounds with various applications.

InChI:InChI=1/C8H2Cl4N2/c9-3-1-4-6(5(10)2-3)13-8(12)14-7(4)11/h1-2H

Upstream product

• 610-24-2 6,8-dichloroquinazoline-2,4(1H,3H)-dione 
• 2789-92-6 3,5-dichloroantranilic acid 

Downstream Products

• 769158-52-3 2-((2,6,8-trichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 76004-92-7 6,8-Dichloro-N²-(3,4-dichloro-phenyl)-N⁴-(1-ethyl-piperidin-3-yl)-quinazoline-2,4-diamine; hydrochloride 

Relevant articles and documents

Synthesis and QSAR of Quinazoline Sulfonamides As Highly Potent Human Histamine H4 Receptor Inverse Agonists

Hit optimization of the class of quinazoline containing histamine H 4 receptor (H4R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H4R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H4R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H4R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds, was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H4R affinity and behave as inverse agonists at the human H4R. In vivo evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline4-amino)-N- phenylethanesulfonamide (54) (pki = 8.31 ± 0.10) revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.